Becton, Dickinson and Company (NYSE:BDX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Seventeen brokerages give Becton, Dickinson and Company (NYSE:BDX) a consensus recommendation of Hold—11 holds and 6 buys—with an average 12‑month price target of $189.08.
• Several major analysts recently revised targets: Jefferies and Argus cut targets to $190 and $180, JPMorgan and RBC lowered to around $175, while Bank of America raised its target to $207, leaving the analyst range roughly $175–$207.
• BDX reported Q results with EPS of $2.91 (vs. $2.81 est.) but revenue missed at $4.49B (vs. $5.15B), set FY2026 guidance of $12.35–$12.65 EPS, and authorized a $10 million share repurchase program.

Shares of Becton, Dickinson and Company (NYSE:BDX - Get Free Report) have received a consensus recommendation of "Hold" from the seventeen brokerages that are presently covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $189.0769.

BDX has been the subject of a number of research analyst reports. Jefferies Financial Group decreased their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Tuesday, February 10th. Argus reduced their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a report on Monday, March 23rd. Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a report on Tuesday, April 14th. JPMorgan Chase & Co. reduced their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating on the stock in a report on Tuesday, February 10th. Finally, Bank of America raised their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a report on Monday, January 5th.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $150.13 on Tuesday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The firm has a market capitalization of $42.75 billion, a P/E ratio of 24.49, a P/E/G ratio of 10.82 and a beta of 0.29. The stock has a 50 day moving average price of $162.67 and a 200 day moving average price of $182.74.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the company earned $3.43 EPS. Becton, Dickinson and Company's quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Crux Wealth Advisors lifted its position in Becton, Dickinson and Company by 0.8% in the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier's stock valued at $1,222,000 after purchasing an additional 49 shares during the period. Larson Financial Group LLC lifted its position in Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier's stock valued at $627,000 after purchasing an additional 53 shares during the period. Camelot Portfolios LLC lifted its position in Becton, Dickinson and Company by 1.5% in the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier's stock valued at $688,000 after purchasing an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 3.6% during the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier's stock valued at $309,000 after acquiring an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp lifted its position in shares of Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier's stock valued at $1,185,000 after acquiring an additional 57 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.